Herzklappenfehler und Endokarditis

  • Dieter Horstkotte
  • Cornelia Piper
Chapter

Auszug

Der allgemeine Behandlungsplan bei Patienten mit chronischen Herzklappenfehlern umfasst

  • die Prävention typischer Komplikationen

  • bei Fehlern mit chronischer Volumenbelastung die medikamentöse Behandlung mit dem Ziel, die Progression zu verlangsamen

  • die Beratung über angemessene Belastungen in Beruf und Freizeit und

  • die Verlaufsbeobachtung, um den optimalen Interventionszeitpunkt festlegen zu können. Dabei ist zu berücksichtigen, dass die klinische Symptomatik häufig nicht mit der hämodynamischen Schwere des Klappenfehlers oder der myokardialen Adaptation an die veränderten Lastbedingungen korre-liert.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Braunwald E, Zipes DP, Libby P. (1997) Heart Disease, a Textbook of Cardiovascular Medicine, 6th edition, 2001; W.B. Saunders Company, Carabello BA, Crawford FA. Valvular Heart Disease. New Engl J Med. 337:32–41Google Scholar
  2. Carabello BA, Crawford FA (1997) Valvular Heart Disease. New Engl J Med. 337:32–41PubMedCrossRefGoogle Scholar
  3. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2006;114:e84–231Google Scholar
  4. Gutschik E (1999) New developments in the treatment of infective endocarditis infective cardiovasculitis. Int J Antimicrob Agents 13:79–92PubMedCrossRefGoogle Scholar
  5. Hering D, Piper C, Horstkotte D (2004) Influence of atypical symptoms and electrocardiographic signs of left ventricular hypertrophy or ST-segment/T-wave abnormalities on the natural history of otherwise asymptomatic adults with moderate to severe aortic stenosis: preliminary communication. J Heart Valve Dis 13:182–187PubMedGoogle Scholar
  6. Horstkotte D (1995) Mikrobiell verursachte Endokarditis, Steinkopff, DarmstadtGoogle Scholar
  7. Horstkotte D on behalf of the Task Force on Infective Endocarditis of the European Society of Cardiology. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis: Executive Summary. Eur Heart J 2004;25:267–276PubMedCrossRefGoogle Scholar
  8. Horstkotte D, Bergemann R (eds) (2001) Antithrombotic management after heart valve replacement: results and consequences of the GELIA study. Proceedings of an International Symposium held on March 30–31, 2001, Bad Oeynhausen, Germany. Eur Heart J 3,Suppl QGoogle Scholar
  9. Khot UN, Novaro GM, Popovic ZB et al. (2003) Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 348:1756–1763PubMedCrossRefGoogle Scholar
  10. Meyer T, Reiter H, Mirzaie M, Hasenfuß G, Unterberg C (2000) Symptomatik der primären Endokardfibroelastose im Erwachsenenalter. Dtsch med Wochenschr 125:168–171Google Scholar
  11. Moder KG, Miller TD, Tazelaar HD (1999) Cardiac Involvement in Systemic Lupus Erythematosus. Mayo Clin Proc 74:275–284PubMedCrossRefGoogle Scholar
  12. Murphy PT, Fenelly DF, Stuart M, O’Donnell JR (1990) Alphainterferon in a case of hypereosinophilic syndrome. Br J Haematol 75:619–620PubMedGoogle Scholar
  13. Mylonakis E, Calderwood SB (2001) Infective endocarditis in adults. N Engl J Med 345:1318–1330PubMedCrossRefGoogle Scholar
  14. Neumayer U, Schmidt HK, Fassbender D, Mannebach H, Bogunovic N, Horstkotte D (2002) Early (threemonth) results of percutaneous mitral valvotomy with the Inoue balloon in 1,123 consecutive patients comparing various age groups. Am J Cardiol 90:190–193PubMedCrossRefGoogle Scholar
  15. Piper C, Hetzer R, Körfer R, Bergemann R, Horstkotte D (2002) The importance of secondary mitral valve involvement in primary aortic valve endocarditis: the kissing vegetation. Eur Heart J 23:7986CrossRefGoogle Scholar
  16. Piper C, Wiemer M, Schulte HD, Horstkotte D (2001) Stroke is not a contraindication for urgent valve replacement in acute infective endocarditis. J Heart Valve Dis 10:703–711PubMedGoogle Scholar
  17. Piper C, Horstkotte D (2004) State of the Art in Anticoagulation Management J Heart Valve Dis 13(Suppl 1): S76–S80PubMedGoogle Scholar
  18. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer, G Baumgartner H. Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis; New Engl J Med; 2000; 343: 611–617PubMedCrossRefGoogle Scholar
  19. Salem DN, Stein PD, Al-Ahmad A, Bussey H, Horstkotte D, Miller N, Pauker SG (2004) Antithrombotic therapy in valvular heart disease — native and prosthetic. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(Suppl): 457S–482SPubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2007

Authors and Affiliations

  • Dieter Horstkotte
    • 1
  • Cornelia Piper
    • 1
  1. 1.Kardiologische KlinikHerz- und Diabeteszentrum Nordrhein-WestfalenBad Oeynhausen

Personalised recommendations